Wikler A
Ann N Y Acad Sci. 1976;282:126-47. doi: 10.1111/j.1749-6632.1976.tb49893.x.
Tolerance at all levels of complexity in the brain involves "learning" in the sense of the acquisition of compensatory adaptations to the consequences of the presence of a drug-produced disturbance in function. Depending on the function, species, and dose of cannabis, "tissue tolerance," behaviorally augmented (to provide the presence of the disturbed function) or not, develops at different rates or not all (e.g., to impairment of the logical sequence of thoughts, to which no tolerance has yet been demonstrated). "Dispositional tolerance" (increased rate of metabolism of delta 9-THC due to enzyme induction) may play a role in the development of tolerance or "reverse tolerance" to cannabis in man. There is evidence that for the label "high," placebo effects may account for the "reverse tolerance" seen in experienced users on smoking (but not on ingestion of delta 9-THC or placebo) along with evidence of residual tolerance to other not-so-labeled effects of the drug. Dependence on cannabis, in the sense of abstinence phenomena on abrupt withdrawal of delta 9-THC, has been demonstrated in monkeys made tolerant to delta 9-THC given four times daily for about 1 month. In man, physiologic marijuana abstinence signs have not been demonstrated, but behavioral (and some physiologic) abstinence phenomena have been reported in heavy users of hashish or ganja. The between-dose hyperirritability and dysphoria reported to occur in experimental studies on chronic marijuana intoxication may actually be early and short-lived abstinence changes. In the West, where marijuana with relatively low delta 9-THC content is widely smoked, dependence in the sense of drug-seeking behavior appears to be less a function of any pharmacologic reinforcing properties the drug may have than of secondary (conditioned) reinforcement derived from the social milieu in which the marijuana is smoked. In cultures where marijuana of higher delta 9-THC content, hashish, or ganja is used, pharmacologic reinforcement (through suppression of abstinence changes) may play a greater role in maintaining drug-seeking behavior.
大脑在所有复杂程度层面上的耐受性都涉及“学习”,即获得对药物导致功能紊乱后果的代偿性适应。根据大麻的功能、物种和剂量,“组织耐受性”(无论是否通过行为增强以表现出功能紊乱)会以不同速度发展,或者根本不会发展(例如,对思维逻辑顺序受损就尚未证明存在耐受性)。“处置耐受性”(由于酶诱导导致Δ⁹-四氢大麻酚代谢速率增加)可能在人类对大麻耐受性或“反向耐受性”的发展中起作用。有证据表明,对于“兴奋”这一标签效应,安慰剂效应可能是有经验的使用者在吸烟(而非摄入Δ⁹-四氢大麻酚或安慰剂)时出现“反向耐受性”的原因,同时也有证据表明对该药物其他未如此标记的效应存在残余耐受性。在每天给予Δ⁹-四氢大麻酚约1个月、持续约1个月从而产生耐受性的猴子身上,已证明存在对Δ⁹-四氢大麻酚突然戒断时的戒断现象意义上的对大麻的依赖性。在人类中,尚未证明存在生理性大麻戒断体征,但在重度大麻或印度大麻使用者中报告了行为性(以及一些生理性)戒断现象。在慢性大麻中毒的实验研究中报告的剂量间过度易怒和烦躁不安实际上可能是早期且短暂的戒断变化。在西方,广泛吸食Δ⁹-四氢大麻酚含量相对较低的大麻,寻求药物行为意义上的依赖性似乎与其说是该药物可能具有的任何药理学强化特性的作用,不如说是来自吸食大麻的社会环境的次级(条件性)强化作用。在使用Δ⁹-四氢大麻酚含量较高的大麻、印度大麻或大麻的文化中,药理学强化(通过抑制戒断变化)可能在维持寻求药物行为中起更大作用。